Physician profile
William Creighton
NPI 1245371814
$8,282.57
in general payments reported to CMS, 2019-2025
16 companies · $246 in 2025
The $246 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,453 · 2020: $224 · 2021: $197 · 2022: $445 · 2023: $1,101 · 2024: $616 · 2025: $246.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,963.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,963.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $5,125.43 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $1,059.51 | 2019-2025 | Breztri, Airsupra, Tezspire |
| Genzyme Corporation | $685.35 | 2023-2025 | |
| Glaxosmithkline, LLC. | $669.55 | 2019-2023 | Nucala, Trelegy Ellipta, Arexvy |
| Regeneron Healthcare Solutions, INC. | $164.54 | 2022-2024 | Dupixent |
| Novartis Pharmaceuticals Corporation | $126.55 | 2022-2025 | |
| Amgen INC. | $110.83 | 2022-2025 | Tezspire |
| Takeda Pharmaceuticals U.S.A., INC. | $71.13 | 2020-2022 | |
| Biocryst Pharmaceuticals, INC. | $56.84 | 2020 | |
| Biocryst US Sales Co., LLC | $54.89 | 2022-2023 | Orladeyo |
| Optinose US, INC. | $40.53 | 2019-2020 | |
| Pfizer INC. | $36.85 | 2021-2022 | |
| Shire North American Group INC | $25.20 | 2019 | |
| Pharming Healthcare, INC. | $24.50 | 2021 | |
| Galderma Laboratories, L.P. | $17.32 | 2025 | Nemluvio |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $13.55 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Creighton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.